- Home
- AZ vs PRLD Comparison
AZ vs PRLD Comparison
Compare AZ & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AZ | PRLD |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | Canada | United States |
| Employees | 89 | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 241.0M | 207.5M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AZ | PRLD |
|---|---|---|
| Price | $6.99 | $3.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $20.00 | $4.67 |
| AVG Volume (30 Days) | ★ 347.0K | 242.3K |
| Earning Date | 05-14-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,140,000.00 |
| Revenue This Year | $30.87 | $320.10 |
| Revenue Next Year | $480.68 | $100.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 73.43 |
| 52 Week Low | $5.00 | $0.61 |
| 52 Week High | $12.36 | $4.19 |
Technical Indicators
Market Signals| Indicator | AZ | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 66.43 | 55.89 |
| Support Level | $6.91 | $1.02 |
| Resistance Level | $7.47 | $4.10 |
| Average True Range (ATR) | 0.48 | 0.35 |
| MACD | 0.21 | -0.05 |
| Stochastic Oscillator | 97.50 | 35.90 |
Price Performance
Historical ComparisonAbout AZ A2Z Smart Technologies Corp.
A2Z Cust2Mate Solutions Corp is engaged in creating shopping carts. With the help of a user-friendly smart algorithm, touch screen, and other technologies, the company streamlines the retail shopping experience by scanning purchased products and enabling in-cart payment so that customers can simply pick & go, and bypass long cashier checkout lines.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.